CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • Use Cases

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Loading
Home
News
Psychedelics startup Nue Life Health rolls out free version of its ketamine therapy tracking app

From TechCrunch

By Mike Butcher

June 15, 2023

Psychedelics startup Nue Life Health rolls out free version of its ketamine therapy tracking app

Psychedelics startup Nue Life Health rolls out free version of its ketamine therapy tracking app

Nue Life Health is a U.S.-based telemedicine startup that combines psychedelic-assisted therapies and a health tracking app. Previously, the app was only offered as part of its own internal service. However, the startup is now opening up its “Nue app” and its “Nue score” available for free to any patient undergoing ketamine therapy, not just its own. The FDA has approved a variant of Ketamine called “Esketamine” as a medication for depression.

The Nue Life app allows patients undergoing ketamine therapy in the U.S. to join Nue Life’s membership services to complement their drug therapy. The app has biometric data integration (Apple Healthkit and Google Fit), and accesses the ‘Nue Score’ progress tracking. The at-home ketamine therapy combines music therapies and a data-led, ‘quantified self’ approach.

All users in the United States who are undergoing ketamine therapy across all treatment modalities, including via lozenges, intramuscular (IM) and intravenous (IV), will be able to access the Nue Life app.

As a result, it’s likely that this will expand Nue Life’s market reach, as it rolls out these new services.

Last year Nue Life said raised a $23 million Series A equity financing led by Obvious Ventures (co-founded by Ev Williams, co-founder of Twitter), which was part venture debt and part equity. This followed a seed round in 2021.

The company has also now completed an extra $1.9m financing round from existing investors to back the app roll-out for free.

Nue Life says it now delivers “at-home” ketamine therapy to over eight thousand patients across the U.S. combined with libraries, apps, and aftercare programs.

In a statement, Nue Life co-founder and CEO Juan Pablo Cappello said: “We have seen that patients who take advantage of our full program experience a 20-30% improvement over the baseline of drug-only therapy. We are now excited to make all these tools, content and preparation and after-care programs available to all users that may be undergoing ketamine treatment with providers across the US, including at-home or within clinics or offices.”

Nue Life has also appointed Dr. Frank Drummond as its new Chief Medical Officer. Dr. Drummond was formerly the national CMO of HCA’s behavioral health practice.

Nue Life competes with Mindbloom, as well as Field Trip Health, which also has physical treatment centers.

In March this year, TechCrunch interviewed Mindbloom’s CEO Dylan Beynon about how he saw the future of psychedelic mental health.

Psychedelics startup Nue Life Health rolls out free version of its ketamine therapy tracking app by Mike Butcher originally published on TechCrunch

Most Recent

Startup Abby Care raises $82 million to turn family members into paid caregivers

As a kid, Havi Nguyen sometimes missed school to translate at doctor's appointments, and was managing Medicaid paperwork for her family, who had recently immigrated from Vietnam.

Oct 18, 2026

795 accounts funded by ADI Predictstreet's own fee-collecting wallet drove 99% of the FIFA-partnered prediction market's activity since late August

ADI Predictstreet, backed by Abu Dhabi's royal family, paid close to $150 million for advertising rights during the World Cup

Oct 18, 2026

China's CXMT sees shares drop over 6% as investors look past chipmaker's profit turnaround

CXMT shares fell over 6% on Monday after the company released its earnings forecast for the first nine months of 2026.

Oct 18, 2026

World launches World ID suite for banks, makes Zoom deepfake check generally available

The identity project co-founded by OpenAI CEO Sam Altman named Bain Capital and VanEck Funds among its design partners but did not name a bank that has started using the product.

Oct 18, 2026

Similar Posts

Stellar Sleep app gets initial funding to awaken root cause of chronic insomnianin users

Stellar Sleep’s mobile app taps into psychological methods to help users breaknthe cycle of those frequent nights awake.

Feb 6, 2024

Being is an app that wants to help users map out and address mental health concerns

Being, a Delaware-based startup, is on a mission to scale its mental health app, which aims to help users create a map of their concerns to better navigate their everyday issues. The company, which exhibited as part of the Battlefield 200 at TechCrunch Disrupt, was founded in 2020 by CEO Varun Gandhi and CTO Abhishek […]

Sep 28, 2023

A new $25M fund aims to give UK mental health startups a shot in the arm

In case you hadn’t noticed, there are a lot of mental health startups out there these days, many of which were prompted to launch following the pandemic and the subsequent widespread focus on mental health. However, they often have scant relationships with clinical trials or healthcare systems. A new venture from the U.K.’s KHP Ventures, is planning to correct that by raising a new £20 million ($25.5 million) fund specifically aimed at accelerating startups that are addressing depression, anxi

Dec 12, 2024

Glow Debuts A New App For Tracking Baby's Milestones, Plus Premium Plans

Glow launches the Glow Baby app tracking CDC-based milestones and introduces the Glow Premium subscription across its app suite, reporting 3M users and 200K pregnancies.

Feb 24, 2016